anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The use of an intravascular cooling element to induce hypothermia in connection with a medical procedure. According to a first aspect of the present invention, a coronary bypass procedure is conducted in which a patient's blood is oxygenated with the patient's lungs and in which blood is circulated using the patient's heart or using an intracorporeal pump. The procedure preferably comprises: (a) positioning a heat transfer element in a blood vessel of a patient; (b) cooling the body of the patient to less than 35 DEG C, more preferably 32+/-2 DEG C, using the heat transfer element; and (c) forming a fluid communicating graft between an arterial blood supply and the coronary artery. The body of the patient is preferably heated to about 37 DEG C using the heat transfer element subsequent to the step of forming the fluid communicating graft. According to a further aspect of the invention, a hypothermic medical procedure is provided while a patient is in a conscious or semiconscious state, comprising (a) administering a beta-blocking drug to the patient; b) delivering a heat transfer element to a blood vessel of the patient; and c) cooling a region of the patient or the body of the patient to less than 35 DEG C using the heat transfer element. According to yet a further aspect of the invention, a method is provided which comprises: (a) inducing hypothermia in a human patient in need of neural protection due to ischemic neural conditions, the step of inducing hypothermia comprising (i) positioning a heat transfer element in a blood vessel of a patient and (ii) cooling the body of the patient or a region of the body of the patient to less than 35 DEG C using the heat transfer element; and (b) administering to the patient a therapeutic agent selected from (i) a free-radical scavenger, (ii) an N-methyl-D-aspartame receptor antagonist and (iii) an antipyretic agent, the therapeutic agent being provided in an amount effective to supplement neural protection provided by the step of inducing hypothermia.
Psoriatic arthritis (PsA) predominantly emerges in individuals previously diagnosed with psoriasis (PsO), offering a unique opportunity to study the transition from PsO to PsA. This progression provides a window to identify characteristics of PsO patients who may develop PsA, facilitating early intervention and potentially informing prevention and treatment strategies. This review evaluates a wide array of research focusing on various risk factors for PsA development. These factors span demographic characteristics, concomitant diseases and habits, characteristics of skin and nail psoriatic disease, and symptoms and imaging abnormalities associated with PsA. By summarising the existing literature, this review critically examines each risk factor, highlighting the strengths and limitations inherent in the studies. Each section of the review not only summarises the current state of knowledge but also includes an expert opinion, culminating in a final concluding remark. This integration allows physicians to utilise the confluence of established literature and ongoing clinical experience, facilitating a rationalised decision-making process that is deeply informed by both empirical evidence and practical insights.
Diagnostic testing followed by isolation of identified cases with subsequent tracing and quarantine of close contacts-often referred to as test-trace-isolate-and-quarantine (TTIQ) strategy-is one of the cornerstone measures of infectious disease control. The COVID-19 pandemic has highlighted that an appropriate response to outbreaks of infectious diseases requires a firm understanding of the effectiveness of such containment strategies. To this end, mathematical models provide a promising tool. In this work, we present a delay differential equation model of TTIQ interventions for infectious disease control. Our model incorporates the assumption of limited TTIQ capacities, providing insights into the reduced effectiveness of testing and tracing in high prevalence scenarios. In addition, we account for potential transmission during the early phase of an infection, including presymptomatic transmission, which may be particularly adverse to a TTIQ based control. Our numerical experiments inspired by the early spread of COVID-19 in Germany demonstrate the effectiveness of TTIQ in a scenario where immunity within the population is low and pharmaceutical interventions are absent, which is representative of a typical situation during the (re-)emergence of infectious diseases for which therapeutic drugs or vaccines are not yet available. Stability and sensitivity analyses reveal both disease-dependent and disease-independent factors that impede or enhance the success of TTIQ. Studying the diminishing impact of TTIQ along simulations of an epidemic wave, we highlight consequences for intervention strategies.
The objective of this study was to evaluate whether RSV inhibits neutrophil extracellular traps (NETs) that induce joint hyperalgesia in C57BL/6 mice after adjuvant-induced arthritis. A subplantar injection of Freund's complete adjuvant was administered to C57BL/6 mice on day 0 for immunization in the AIA model. Resveratrol (RSV, 25 mg/kg) was administered intraperitoneally once daily starting on day 22 and continuing for two weeks. The effects of mechanical hyperalgesia and edema formation have been assessed in addition to histopathological scoring. Mice were sacrificed on day 35 to determine cytokine levels and PADI4 and COX-2 expression levels. ELISA was used to quantify neutrophil extracellular traps (NETs) along with neutrophil elastase-DNA and myeloperoxidase-DNA complexes in neutrophils. An immunohistochemical stain was performed on knee joints to determine the presence of nuclear factor kappa B p65 (NF-kappaB p65). AIA mice were found to have higher levels of NET in joints and their joint cells demonstrated an increased expression of the PADI4 gene. Treatment with RSV in AIA mice (25 mg/kg, i.p.) significantly (P<0.05) inhibited joint hyperalgesia, resulting in a significant increase in mechanical threshold, a decrease in articular edema, a decrease in the production of inflammatory cytokines, increased COX-2 expression, and a decrease in the immunostaining of NF-kappaB. Furthermore, treatment with RSV significantly reduced the amount of neutrophil elastase (NE)-DNA and MPO-DNA complexes, which were used as indicators of NET formation (P<0.05). This study indicates that RSV reduces NET production and hyperalgesia by reducing inflammation mediated by PADI4 and COX-2. According to these data, NETs contribute to joint pain and resveratrol can be used to treat pain in RA through this pathway.
RFA causes tissue destruction through the application of a high frequency alternating current, generating local temperatures above 60°C and leading to coagulative necrosis. The technique has been widely used in many solid organ tumours and has been shown to result in 5-year survival rates comparable to surgery. The technique is currently the standard therapy in hepatocellular carcinoma and colorectal pulmonary metastasis particular in patients that are not suitable for surgery.

The current study would be a multi-center prospective study involving four high volume international institutions. Consecutive patients suffering from solid neoplasms of the liver, stomach and adrenals would be recruited. EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea). The primary outcome would be the overall adverse events rate. Secondary outcomes include mortality, technical success rate, completion ablation rate, 1 \& 3 year overall and disease-free survival.
Identifying biomarkers to predict immune checkpoint inhibitor (ICI) efficacy is warranted. Considering that somatic mutation-derived neoantigens induce strong immune responses, patients with a high tumor mutational burden reportedly tend to respond to ICIs. Therefore, the original function of neoantigenic mutations and their impact on the tumor microenvironment (TME) require attention. RNF43 is a type of RING E3 ubiquitin ligase, and long-term survivors in most cancers had conserved patterns of mutations of RNF43. Also, high microsatellite instability patients had a higher RNF43 mutation rate compared with microsatellite stability tumor patients, who were more sensitive to ICI treatment. Therefore, RNF43 has become a promising biomarker of immunotherapy in a wide range of cancers. This review focuses on the up-to-date knowledge of RNF43 mutation in cancer. We summarize the cancer hallmarks involving activities regulated by RNF43 and highlight its extremely sophisticated regulation of WNT signaling and tumor microenvironment. The key genes interacting with RNF43 have also been summarized and discussed. Additionally, we highlight and propose new strategies of targeting RNF43 and RNF43-based combinations with established immunotherapy and combination therapy. These efforts may provide new perspectives for RNF43-based target therapy in cancer.
Amygdala atrophy has been found in frontotemporal dementia (FTD), yet the specific changes of its subregions across different FTD phenotypes remain unclear. The aim of this study was to investigate the volumetric alterations of the amygdala subregions in FTD phenotypes and how they evolve with disease progression. Patients clinically diagnosed with behavioral variant FTD (bvFTD) (n = 20), semantic dementia (SD) (n = 20), primary nonfluent aphasia (PNFA) (n = 20), Alzheimer's disease (AD) (n = 20), and 20 matched healthy controls underwent whole brain structural MRI. The patient groups were followed up annually for up to 3.5 years. Amygdala nuclei were segmented using FreeSurfer, corrected by total intracranial volumes, and grouped into the basolateral, superficial, and centromedial subregions. Linear mixed effects models were applied to identify changes in amygdala subregional volumes over time. At baseline, bvFTD, SD, and AD displayed global amygdala volume reduction, whereas amygdala volume appeared to be preserved in PNFA. Asymmetrical amygdala atrophy (left > right) was most pronounced in SD. Longitudinally, SD and PNFA showed greater rates of annual decline in the right basolateral and superficial subregions compared to bvFTD and AD. The findings provide comprehensive insights into the differential impact of FTD pathology on amygdala subregions, revealing distinct atrophy patterns that evolve over disease progression. The characterization of amygdala subregional involvement in FTD and their potential role as biomarkers carry substantial clinical implications.
A skin care product may comprise a non-solid, multi-phase multi-function skin care composition comprising a translucent base phase, a first opaque phase, and a second opaque phase. The three phases form a stable, visually distinct pattern within a container that is at least partially translucent. The first opaque phase may have a lightness of greater than about 80 and a chroma of less than about 5. The second opaque phase may have a hue from about 35 to about 70. The translucent base phase may include a first chronic skin care active; the first opaque phase may include a skin conditioning agent; and the second opaque may comprise one or more opacifying particulate materials. The skin care product may further comprise a plurality of informational indicium. An array of skin care products comprising a first skin care product and a second skin care product is also disclosed.
A medical device known as an implantable therapeutic substance delivery device is configured for implanting in humans to deliver a therapeutic substance such as pharmaceutical compositions, genetic materials, and biologics to treat a variety of medical conditions such as pain, spasticity, cancer, and many other conditions. The infusion device incorporates a stepper motor that controls the infusion flow rate during the service life of the device. The stepper motor is controlled by continuously varying electrical pulse parameters based on the continuously decreasing power source voltage during the service life of the substance delivery device. In particular the stepper motor electrical pulse parameters, especially duty cycle, are selected to efficiently compensate for decreasing battery voltage thereby optimizing the motor performance while maximizing the power source service life. The infusion device has a housing, a power source, a therapeutic substance reservoir, a therapeutic substance pump, and electronics. Many embodiments of the therapeutic substance delivery device with optimized pump motor drive and its methods of operation are possible.
1. Symptomatic response to nizatidine therapy does not preclude the presence of gastric malignancy.

  2. Because nizatidine is excreted primarily by the kidney, dosage should be reduced in patients with moderate to severe renal insufficiency (see DOSAGE AND ADMINISTRATION).

  3. Pharmacokinetic studies in patients with hepatorenal syndrome have not been done. Part of the dose of nizatidine is metabolized in the liver. In patients with normal renal function and uncomplicated hepatic dysfunction, the disposition of nizatidine is similar to that in normal subjects.
<P>PROBLEM TO BE SOLVED: To provide a composition having a broad antibacterial spectrum which is biologically available and excellent in absorbability.  <P>SOLUTION: The invention provides the local-ophthalmic composition comprising a quinolone carboxylic acid derivative. In one embodiment, the composition allows sustained release of the quinolone carboxylic acid derivative. In one embodiment, the composition further comprises a carboxy group-containing polymer. In one embodiment, the carboxy group-containing polymer accounts for about 0.1-6.5 wt.% of the composition based on a total weight of the composition.  <P>COPYRIGHT: (C)2010,JPO&INPIT
BACKGROUND: Perioperative hypotension is common and associated with adverse patient outcomes. Vasoactive agents are often used to manage hypotension, but the ideal drug, dose and duration of treatment has not been established. With this scoping review, we aim to provide an overview of the current body of evidence regarding the vasoactive agents used to treat perioperative hypotension in non-cardiac surgery.
METHODS: We included all studies describing the use of vasoactive agents for the treatment of perioperative hypotension in non-cardiac surgery. We excluded literature reviews, case studies, and studies on animals and healthy subjects. We posed the following research questions: (1) in which surgical populations have vasoactive agents been studied? (2) which agents have been studied? (3) what doses have been assessed? (4) what is the duration of treatment? and (5) which desirable and undesirable outcomes have been assessed?
RESULTS: We included 124 studies representing 10 surgical specialties. Eighteen different agents were evaluated, predominantly phenylephrine, ephedrine, and noradrenaline. The agents were administered through six different routes, and numerous comparisons between agents, dosages and routes were included. Then, 88 distinct outcome measures were assessed, of which 54 were judged to be non-patient-centred.
CONCLUSIONS: We found that studies concerning vasoactive agents for the treatment of perioperative hypotension varied considerably in all aspects. Populations were heterogeneous, interventions and exposures included multiple agents compared against themselves, each other, fluids or placebo, and studies reported primarily non-patient-centred outcomes.
Single Bond 2 is a traditional etch and rinse adhesive system. It is used to bond the composite resin to the dental tissues. It was applied to the cavities opened in accordance with the manufacturer's instructions.
Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
The invention discloses a porcine parvovirus L strain and use thereof in preparation of porcine parvovirus inactivated vaccines. In the invention, microbial preservation number of the separated strain is CGMCC No. 3352. The strain is highly homologous with an NADL-2 strain and a China strain and keeps high reproduction, and the viruses are stable. Oil adjuvant is added into antigen liquid which inactivates the viruses by using binary ethylenimine to prepare the bidirectional oil-emulsion inactivated vaccines; and the prepared inactivated vaccines are applied in a vaccine inoculation experiment of 10,276 pigs (most of which are first farrowing sows), and in the experiment, an immune dosage of 2 millimeters is given to each pig through muscle injection, and each time of inactivated vaccine inoculation can obtain an immune period of over 6 months. Under the conditions that a 10 millimeter overdose vaccine is injected into a pig and that single dose inoculation is repeatedly carried out for three times, no abnormal reaction happens, which proves that the inactivated vaccines have high immunogenicity and safety.
The present invention relates to short peptides or salts thereof which can be modified with appropriate hydrophobic tails to generate amphiphilic molecules useful for the intracellular delivery of molecules of biological interest. Thus, the invention also relates to the amphiphilic molecules and to the complexes between said amphiphilic molecules and the molecules of biological interest. In addition, the invention refers to the use of said peptides, said amphiphilic molecules and said complexes for the delivery of molecules of biological interest. The invention relates to said peptides or salts thereof, said amphiphilic molecules and said complexes for use in medicine, particularly for use as a vaccine. Methods for the preparation of the amphiphilic molecules and the complexes of the invention are also contemplated. Finally, the invention relates to novel amino acids useful in the synthesis of the peptides and molecules of the invention.
Participants with higher-risk MDS or CMML will receive azacitidine 75 mg/m\^2 BSA subcutaneously or Intravenously per local label on Days 1 through 7 and cusatuzumab 20 mg/kg IV on Days 3 and 17 of each 28-day cycle. Participants will be treated until disease progression; relapse from CR, PR, mCR; transformation to AML; death; or unacceptable toxicity.
FIELD: dentistry.SUBSTANCE: group of inventions relates to a curable composition which is suitable for use as a dental material, and to a corresponding dental material. Disclosed curable composition contains a polymerizable monomer component (A), spherical filler (B) having average particle size in range from 260 nm to 1000 nm, and polymerisation initiator (C). At that, 90 % or more of separate particles that make spherical filler (B) are within ±5 % of average particle size. Polymerizable monomer component (A) having refraction index (25 °C) in range of 1.38 to 1.55 and spherical filler (B), which is spherical composite oxide particles based on silicon dioxide and titanium oxide and having refraction index (25 °C) of particles in range of 1.45 to 1.58, are respectively selected so that they satisfy condition (X1) represented by (1): nP<nF (1), where nP is refraction index at 25 °C of polymer obtained by polymerisation of polymerizable monomer component (A), and nF is refraction index at 25 °C of spherical filler (B). Difference between the refractive index of the spherical filler (B) nF (25 °C) and the refraction index of the polymer from the polymerizable monomer component (A) nP (25 °C) is 0.001 or more. At that, when performing measurement for hardened composition in condition of formed hardened article having thickness of 1 mm, using differential colorimeter, said cured article emits colored light having brightness (V) of less than 5 and chromaticity (C) of 0.05 or more in colorimetric values according to Munsell Color System on a black background, and having brightness (V) 6 or more and chromaticity (C) less than 2 in colorimetric values according to Munsell Color System on a white background. Also disclosed is a dental filling material consisting of said curable composition.EFFECT: filling material provides excellent comfort and excellent aesthetic appearance due to that the composition has a well-adjusted color tone of appearance without using a dye or pigment and shows low decolouration or color change.5 cl, 4 tbl, 9 ex
Hepatitis B virus (HBV) infection poses a challenge to global public health. Persistent liver infection with HBV is associated with an increased risk of developing severe liver disease. The complex interaction between the virus and the host is the reason for the persistent presence of HBV and the risk of tumor development. Chronic liver inflammation, integration of viral genome with host genome, expression of HBx protein, and viral genotype are all key participants in the pathogenesis of hepatocellular carcinoma (HCC). Epigenetic regulation in HBV-associated HCC involves complex interactions of molecular mechanisms that control gene expression and function without altering the underlying DNA sequence. These epigenetic modifications can significantly affect the onset and progression of HCC. This review summarizes recent research on the epigenetic regulation of HBV persistent infection and HBV-HCC development, including DNA methylation, histone modification, RNA modification, non-coding RNA, etc. Enhanced knowledge of these mechanisms will offer fresh perspectives and potential targets for intervention tactics in HBV-HCC.
PURPOSE: A cosmetic composition is prepared from a mixture of hydrophilic materials in an aqueous phase and a mixture of lipophilic materials in an organic phase, to provide a uniform product. CONSTITUTION: The cosmetic composition comprises a medium containing a liquid organic phase and an aqueous emulsion phase as a physiologically acceptable medium thickened with associated polyurethane. The associated polyurethane content is more than 5 milligrams/square meter of the organic-in-water developed area and 2 to 20 wt.% based on the total weight of the composition. The associated polyurethane includes a sequence or craft polymer having at least two C6-C30 alkyl chains separated by a hydrophilic sequence. The composition has a viscosity of 1,000 to 10,000 cp (i.e., 1 to 10 Ps.s) measured with 100 s¬(-1) at 25°C. The physiologically acceptable medium is an organic-in-water emulsion. The liquid organic phase content is 0.1 to 30 wt.% based on the total weight of the composition.